PUFA, psoriasis and atherosclerotic CVD: evidence from the National Health and Nutrition Examination Survey database 2003-2006 and 2009-2014

• Published in: British journal of nutrition Vol. 133; no. 10; p. 1331
• Main Authors: Li, Yixuan, Li, Xinghui
• Format: Journal Article
• Language: English
• Published: England 28.05.2025
• Subjects: Adult; Aged; Atherosclerosis - epidemiology; Atherosclerosis - etiology; Databases, Factual; Diet; Fatty Acids, Omega-3 - administration & dosage; Female; Humans; Male; Middle Aged; Nutrition Surveys; Psoriasis - complications; Psoriasis - epidemiology; Risk Factors; National Health and Nutrition Examination Survey database; Psoriasis; PUFA; n-3; 10-year atherosclerotic CVD risk
• ISSN: 1475-2662
• DOI: 10.1017/S0007114525103437

This study aimed to investigate the potential effect of PUFA intake on the association between psoriasis and 10-year atherosclerotic CVD (ASCVD) risk. Data of this study were extracted from the National Health and Nutrition Examination Survey database 2003-2006 and 2009-2014. The 10-year ASCVD risk score was calculated based on American College of Cardiology/American Heart Association guidelines, and the subjects were stratified into high 10-year ASCVD risk (≥ 7·5 %) and low 10-year ASCVD risk (< 7·5 %), accordingly. The weighted univariate and multivariate logistic regression models were utilised to evaluate the effect of total PUFA and its subtypes intake on the association between psoriasis and 10-year ASCVD risk. This effect was further evaluated in the subgroup of subjects aged ≥ 60 and < 60 years old. A total of 8705 participants were included, with 41·02 % ( 3571) in the high 10-year ASCVD risk (≥ 7·5 %). We observed subjects with psoriasis (OR 1·65; 95 % CI 1·02, 2·67) and low -3 intake (OR 1·27; 95 % CI 1·025, 1·53) were associated with high 10-year ASCVD risk; no significant association was found between -6 and 10-year ASCVD risk. The moderating effect of -3 intake on the association between psoriasis and 10-year ASCVD risk was observed (OR 2·56; 95 % CI 1·04, 6·26). We also found among the -3 components, -linolenic acid (OR 2·72; 95 % CI 1·10, 6·70) had a more significant moderating effect on the association between psoriasis and 10-year ASCVD risk, especially in the subjects aged < 60 years (OR 2·41; 95 % CI 1·36, 4·28). Adequate intake of -3, especially -linolenic acid, may have potential benefits on improving cardiovascular health in psoriasis patients.